Thus, ITPRIPL1 appears to overexpress in the majority of NSCLC patient tumors and can be detected by our humanized antibody, representing a hallmark of a proteomic biomarker. This evidence concerns the gene ITPRIPL1 and non-small cell lung carcinoma.